Clinical Trial Update: Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of three Argatroban dosing regimens as an anticoagulant during percutaneous coronary intervention has completed; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Unstable Angina

Drugs mentioned

• Argatroban (argatroban)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Coronary Artery Disease, Angina, Unstable | Phase 2 | Status: COMPLETED | Results posted: 2012-12-05